Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Moderate and Severe COVID-19
NCT04392414Phase 2Completed
- Sponsor
- Federal Research Clinical Center of the FMBA
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of COVID-19 convalescent hyperimmune plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Federal Research Clinical Center of the FMBA. Primary endpoint: Number and proportion of patients with normal body temperature at Day 7. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent hyperimmune plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04392414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392414.